Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen s Q4 Revenues Grow 24 Percent as Profit Jumps 63 Percent

NEW YORK, Feb. 28 (GenomeWeb News) - Invitrogen today reported double-digit growth in revenues and profits for the fourth quarter of 2005.


Total receipts for the three months ended Dec. 31, 2005, rose 24 percent to $325.3 million from $262.2 million in the prior-year period. Acquisitions generated 17 percent of the quarterly revenue growth, Invitrogen said, while currency exchange rates had a negative impact of 4 percent on quarterly revenues, resulting in net organic growth of 11 percent for the period.


Invitrogen reported quarterly organic revenue growth of 12 percent in its BioDiscovery business unit and 8 percent organic growth in its BioProduction business.


Invitrogen's net income for the fourth quarter grew 63 percent to $49.6 million versus $30.5 million for the same quarter in 2004.  


R&D spending rose 36 percent to $27.4 million in the fourth quarter of 2005 from $20 million in the year-ago period.


Invitrogen had $751 million in cash and investments as of Dec. 31, 2005.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.